证券代码：600789 证券简称：鲁抗医药 公告编号：2025—031 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的 审核问询函回复更新的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于近期收到上海证券交易 所（以下简称"上交所"）出具的《关于山东鲁抗医药股份有限公司向特定对象 发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕137 号，以下 简称《问询函》），上交所审核机构对公司向特定对象发行股票申请文件进行了 审核，并形成了问询问题。 公司收到《问询函》后，按照要求会同相关中介机构就《问询函》所列问题 进行了认真研究和逐项落实，根据相关要求对《问询函》有关问题进行了说明和 论证，同时对募集说明书等申请文件的部分内容进行了相应补充和修订，具体内 容详见公司于 2025 年 6 月 18 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于山东鲁抗医药股份有限公司向特定对象发行股票申请文件的审核问询函 的回复》等文件。 根据上 ...

Group 1 - The Alzheimer's concept sector rose by 1.80%, leading the gains among concept sectors, with 18 stocks increasing in value [1][2] - Notable gainers included Hotgen Biotech with a 20% limit up, and other companies like Jingxin Pharmaceutical and Haizheng Pharmaceutical also reached their limit up [1][2] - The sector saw a net inflow of 372 million yuan from main funds, with 17 stocks receiving net inflows, and six stocks exceeding 30 million yuan in net inflow [2][3] Group 2 - The top three stocks by net inflow were Haizheng Pharmaceutical (105 million yuan), Jingxin Pharmaceutical (88.79 million yuan), and Hotgen Biotech (79.62 million yuan) [2][3] - The net inflow ratios for leading stocks were 9.03% for Haizheng Pharmaceutical, 7.51% for Jingxin Pharmaceutical, and 8.09% for Hotgen Biotech [3][4] - Stocks with significant declines included Fujilai, Wohua Pharmaceutical, and Wanbangde, with declines of 1.61%, 1.30%, and 1.29% respectively [1][5]

Core Viewpoint - The company is advancing its "党建链" (Party Building Chain) to empower its "产业链" (Industrial Chain) by enhancing collaboration across innovation, industry, talent, and technology chains, aiming for high-quality development [2]. Group 1: Innovation Chain - The company is establishing a new model for collaborative innovation that includes "source innovation → technology development → achievement transformation → industrial application" through party building [2]. - Collaboration with the Chinese Academy of Sciences has led to the development of trans-aconitic acid, with significant contributions to innovation and talent exchange, culminating in a first-class award from Shandong Province for technological invention [2]. - The global first green bio-manufacturing project for trans-aconitic acid is set to commence production in June 2025 [2]. Group 2: R&D Chain - The company is creating a new collaborative model for R&D that focuses on "core technology breakthroughs → drug clinical applications → drug achievement transformation" [3]. - Joint efforts with China Pharmaceutical University and Peking University People's Hospital are enhancing the development of the innovative drug CIGB-814, which is expected to lead new directions in immunotherapy and cell therapy [3]. - The establishment of the "Innovative Drug Evaluation and Repositioning Laboratory" is a key initiative in advancing the research of CIGB-814 [3]. Group 3: Supply Chain - The company is enhancing upstream and downstream collaboration through party building, ensuring the stability and safety of its supply chain [5]. - Partnerships with companies like Sinopharm Holdings and Henan Renhua Biotech are driving sales growth through collaborative efforts [5]. Group 4: Professional Chain - The company is collaborating with various regulatory and research institutions to improve quality and compliance, thereby enhancing operational efficiency [6]. - Engagement with the Shandong Provincial Department of Ecology and Environment is facilitating the effective implementation of ecological policies and advanced technologies [6]. - The integration of party building with professional guidance is fostering a strong foundation for quality improvement and high-quality development [6].

Company Overview - Shandong Lukang Pharmaceutical Co., Ltd. was established on February 15, 1993, and is located at 88 Deyuan Road, Jining High-tech Zone, Shandong Province [18] - The company is listed on the Shanghai Stock Exchange with the stock code 600789, and its actual controller is the State-owned Assets Supervision and Administration Commission of the Shandong Provincial Government [18][19] - As of December 31, 2024, the total share capital of the company is 898,669,632 shares, with 100% being unrestricted shares [19] Issuance Plan - The company plans to issue shares to no more than 35 specific investors, including its controlling shareholder, Hualu Group, which intends to subscribe for 23.81% of the shares, amounting to no more than 64,201,417 shares [2][3][6] - The total amount of funds raised from this issuance is not expected to exceed 1.2 billion yuan (120,000 million yuan) [8] - The final issuance price will be determined based on the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark date, with a minimum price set at 80% of this average [4][5] Industry Context - The global chemical pharmaceuticals market has shown stable growth, increasing from USD 924.8 billion in 2016 to USD 1,104.7 billion in 2022 [20] - The Chinese chemical pharmaceuticals market reached a scale of 801.2 billion yuan in 2016, experiencing fluctuations due to global public health events but is expected to recover starting in 2023 [20] - Chronic diseases, particularly cardiovascular diseases and diabetes, are key focus areas for the company, with significant patient populations and high medical costs associated with these conditions [21][20] Market Trends - The market for cardiovascular drugs in China has maintained growth from 2015 to 2019, with fluctuations from 2020 to 2022 due to public health events [21] - The market for type 2 diabetes treatment drugs in China has experienced volatility from 2018 to 2022 but is projected to grow steadily due to the introduction of innovative diabetes medications and increased awareness of comprehensive health management [21] - The antibiotic market in China has grown from 145 billion yuan in 2016 to 208 billion yuan in 2023, despite regulatory restrictions on antibiotic use [22]

Key Points - The company announced a cash dividend of 0.112 CNY per share for A shares [1] - The total cash dividend distribution amounts to approximately 100.65 million CNY based on a total share capital of 898,669,632 shares [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on April 29, 2025 [1] - Key dates for the dividend distribution include the record date on June 26, 2025, and the ex-dividend date on June 27, 2025 [1][2] - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited Shanghai Branch [1] - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax [3] - For individual shareholders holding shares for less than one year, the tax will be calculated upon the transfer of shares [3] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax on dividends, resulting in a net dividend of 0.1008 CNY per share [4][5] - The company will not withhold corporate income tax for other institutional investors, allowing them to determine their tax obligations independently [5]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-030 山东鲁抗医药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.112元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/26 | － | 2025/6/27 | 2025/6/27 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/26 | － | 2025/6/27 | 2025/6/27 | 四、 分配实施办法 1. 实施办法 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记 日上海证券交易所收市 ...

证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 （山东省济宁高新区德源路 88 号） 2024 年度向特定对象发行 A 股股票 保荐机构（主承销商） 募集说明书（修订稿） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年六月 山东鲁抗医药股份有限公司 募集说明书（修订稿） 公司声明 1、本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资料 不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整性承担相 应的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务会 计资料真实、完整。 3、中国证监会、上海证券交易所对本次发行所作的任何决定或意见，均不表明其 对申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明 均属虚假不实陈述。 4、根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发行 人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承担证券依 法发行后因发行人 ...

上市保荐书 保荐机构 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 关于山东鲁抗医药股份有限公司 2024 年度向特定对象发行 A 股股票 之 二〇二五年六月 山东鲁抗医药股份有限公司 上市保荐书 上海证券交易所： 中国国际金融股份有限公司（以下简称"保荐机构"、"保荐人"、"本机构"或 "中金公司"）接受山东鲁抗医药股份有限公司（以下简称"鲁抗医药"、"发行人" 或"公司"）的委托，就发行人 2024 年度向特定对象发行 A 股股票并在主板上市事项 （以下简称"本次发行"）出具本上市保荐书。 保荐机构及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发行上市保荐业务管 理办法》（以下简称"《保荐办法》"）、《上市公司证券发行注册管理办法》（以下 简称"《注册管理办法》"），以及《上海证券交易所股票上市规则》（以下简称"《上 市规则》"）、《上海证券交易所发行上市审核规则适用指引第 2 号——上市保荐书内 容与格式》（以下简称"《指引第 2 号》"）等法律法规和中国证券监督管理委员会（以 下简称"中国 ...

和信会计师事务所（特殊普通合伙） 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 和信综字（2025）第 000300 号 二〇二五年六月 7-2-1 和信会计师事务所（特殊普通合伙） 关于山东鲁抗医药股份有限公司 向特定对象发行股票申请文件的 审核问询函的回复 和信综字（2025）第 000300 号 上海证券交易所： 贵所于 2025 年 5 月 9 日出具的上证上审（再融资）〔2025〕137 号《关于山东鲁抗 医药股份有限公司向特定对象发行股票申请文件的审核问询函》（以下简称"问询函"） 已收悉，山东鲁抗医药股份有限公司（简称"鲁抗医药"、"发行人"、"公司"）及我们 对问询函所列问题进行了逐项落实、核查，现对问询函问题回复如下： 问题 3、关于经营情况 根据申报材料，1）报告期各期，公司营业收入分别为 562,144.19 万元、614,672.14 万元和 623,309.02 万元，归母净利润分别为 13,801.31 万元、24,617.18 万元及 39,461.57 万元，销售净利率分别为 2.55%、4.18%和 6.55%。2）公司外销收入分别为 76,7 ...

北京市通商律师事务所 关于山东鲁抗医药股份有限公司2024年度 向特定对象发行A股股票的 补充法律意见书 二〇二五年六月 中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024 年度 向特定对象发行 A 股股票的 补充法律意见书 山东鲁抗医药股份有限公司： 北京市通商律师事务所（以下简称"本所"）是具有中华人民共和国（为法律 意见书之目的，不包括香港特别行政区、澳门特别行政区和台湾地区，以下简称 "中国"）法律执业资格的律师事务所。本所受山东鲁抗医药股份有限公司（以下 简称"鲁抗医药"、"发行人"、"公司"或"上市公司"）委托，作为鲁抗医药 2 ...